• Arcutis Biotherapeutics director Howard G. Welgus sold 7,144 common shares on May 1, 2026.
• Sale priced at weighted average USD 22.99 per share.
• Direct holdings stood at 32,600 shares following transaction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcutis Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001801050-26-000002), on May 05, 2026, and is solely responsible for the information contained therein.